Related Experiment Videos
Mitomycin is active against refractory germ-cell tumors. A phase II study
P Hoskins1, C M Coppin, N Murray
1Division of Medical Oncology, University of British Columbia, Vancouver, Canada.
American Journal of Clinical Oncology
|February 1, 1990
Summary
Mitomycin showed activity in male patients with platinum-resistant nonseminomatous germ-cell tumors. Despite high toxicity, especially hematological and pulmonary, responses were observed in this heavily pretreated group.
Area of Science:
- Oncology
- Medical Oncology
- Pharmacology
Background:
- Nonseminomatous germ-cell tumors (NSGCT) are a significant concern in male reproductive health.
- Platinum analogues are standard first-line chemotherapy for NSGCT.
- Drug resistance, particularly to platinum compounds, necessitates alternative therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy and toxicity of mitomycin as a single-agent therapy.
- To assess mitomycin's activity in patients with advanced NSGCT refractory to platinum-based treatments.
- To characterize the safety profile of mitomycin in a heavily pretreated patient population.
Main Methods:
- Single-agent mitomycin therapy was administered to seven male patients.
- Patients had histologically confirmed nonseminomatous germ-cell tumors.
- Tumor response and adverse events were closely monitored.
Main Results:
- Mitomycin demonstrated activity in this resistant NSGCT cohort.
- One complete response (18 weeks) and one partial response (20 weeks) were documented.
- High toxicity was observed, notably hematological and pulmonary adverse events.
Conclusions:
- Mitomycin can be an active agent in platinum-resistant NSGCT.
- Careful monitoring for significant toxicities, particularly hematological and pulmonary, is crucial.
- Further investigation may be warranted in select patient populations.